Loading stock data…
DVA
$151.65-3.49 (-2.25%)
Market ClosedLast close May 1
DaVita Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
DaVita Inc. in the Healthcare sector is trading at $151.65. The stock is currently near its 52-week high of $159.42, remaining 14.1% above its 200-day moving average. Technical signals show neutral RSI of 50 and bullish MACD crossover, explaining why DVA maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$151.65
Potential Downside
148%
Whystock Fair Value$-72.75
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Mean target$151.71+0.0%
Range$126.00 – $190.00
Fundamentals
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.19B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
16.03
Beta
Defensive asset. Lower volatility than the S&P 500.
0.92
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-128.44%
Volume
Today's trading volume
446,771
Recent News
Can Execution and Volume Trends Support DaVita's Q1 Earnings?
DVA's first-quarter 2026 results may face seasonal volume and RPT headwinds, but cost discipline, reimbursement growth and IKC contributions could aid results.
Here is What to Know Beyond Why DaVita Inc. (DVA) is a Trending Stock
DaVita HealthCare (DVA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Encompass Health (EHC) Q1 Earnings and Revenues Surpass Estimates
Encompass Health (EHC) delivered earnings and revenue surprises of +6.14% and +0.93%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
DaVita HealthCare (DVA) Ascends While Market Falls: Some Facts to Note
In the latest trading session, DaVita HealthCare (DVA) closed at $151.99, marking a +1.28% move from the previous day.
How Analyst Model Shifts Are Rewriting The DaVita (DVA) Investment Narrative
DaVita’s latest analyst update keeps the fair value estimate steady at US$151.71, while several firms are lifting their individual price targets by US$4 to US$30. Those higher targets are being framed around refreshed models, as analysts reassess upside and risk based on shared assumptions and recent research. As you read on, you will see how these shifting targets can help you track the story the market is building around DaVita over time. Analyst Price Targets don't always capture the full...